This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Sym004 in Patients With Advanced Solid Tumors

This study has been completed.
Information provided by (Responsible Party):
Symphogen A/S Identifier:
First received: April 23, 2010
Last updated: December 23, 2015
Last verified: December 2015
This trial is designed as a multi-centre, open label, dose-escalation, phase I trial and consists of five parts. Part A investigates the safety and PK of escalating weekly dosing of Sym004 in patients with recurrent advanced solid tumors. Part B and C validates the safety, PK and efficacy of weekly dosing of Sym004 at the MTD in a homogenous patient population with advanced mCRC and wild-type KRAS. If MTD equals 12 mg/kg, then part C will explore the 9 mg/kg level. Part B will be initiated when a safe dose has been established in Part A. Part D and E is to validate the safety, PK and efficacy when administered every 2 weeks at doses of 12 mg/kg and 18 mg/kg, respectively. Part F is to validate safety, PK and efficacy when administered with a single loading dose 9 mg/kg followed by weekly doses of 6 mg/kg.

Condition Intervention Phase
Metastatic Colorectal Cancer Biological: Sym004 Phase 1 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Multi-center Phase I Dose Escalation Study to Investigate the Safety and Tolerability of Multiple Doses of Sym004 in Patients With Advanced Solid Tumors

Further study details as provided by Symphogen A/S:

Primary Outcome Measures:
  • Adverse events [ Time Frame: 4 weeks ]
    DLTs (DLT period of 4 weeks after first dose in each patient) along with; incidence and severity of Adverse Events (AEs), including Serious Adverse Events (SAEs) and Suspected Unexpected Serious Adverse Reactions (SUSARs) during the entire trial period.

Secondary Outcome Measures:
  • Objective tumor response according to RECIST criteria verified by imaging techniques [ Time Frame: 01/02/2010 to 31/07/2014 ]
  • Duration of overall response [ Time Frame: 01/02/2010 to 31/07/2014 ]
  • Progression free survival [ Time Frame: 01/02/2010 to 31/07/2014 ]
  • Overall survival [ Time Frame: 01/02/2010 to 31/07/2014 ]
  • Host immune response: ADA monitoring [ Time Frame: 01/02/2010 to 31/07/2014 ]
  • Skin rash according to CTCAE grading [ Time Frame: 01/02/2010 to 31/07/2014 ]
  • Biomarker including CEA and YKL 40 [ Time Frame: 01/02/2010 to 31/07/2014 ]
  • Vital signs and laboratory parameters [ Time Frame: 01/02/2010 to 31/07/2014 ]
  • Pharmakokinetic profile of multiple weekly and biweekly doses of Sym004 [ Time Frame: 24/08/2010 to 31/07/2014 ]

Enrollment: 111
Study Start Date: March 2010
Study Completion Date: May 2015
Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Sym004 Biological: Sym004

In part A, patients in all dose cohorts will continue weekly treatment with the assigned dose of Sym004 until disease progression.

In Part B, patients will continue weekly treatment with the tolerated dose of Sym004 until disease progression.

In Part C, patients will receive weekly doses of Sym004 at the dose level below 12 mg/kg i.e. 9 mg/kg until disease progression.

In Part D and E, patients will receive doses of Sym004 administered every 2 weeks at dose level 12 mg/kg and 18 mg/kg, respectively until disease progression.

In Part F, patients will receive a single loading dose of 9 mg/kg followed by weekly doses of 6 mg/kg.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Part A:

1. Patients with refractory or recurrent advanced late stage solid tumors without available therapeutic options .

Part B, C, D, E and F:

  1. Patients with refractory or recurrent advanced mCRC and wild-type KRAS who have progressed on EGFR Ab treatment.
  2. Patients wit confirmed response while on treatment anti-EGFR Ab treatment.
  3. Documented disease progression during or within 6 months after cessation of anti-EGFR Ab treatment.
  4. Patients must be willing to have a biopsy performed from a tumor lesion at screening and at Visit 6.

Part A, B, C, D, E and F:

  1. Histologically or cytologically confirmed diagnosis of cancer
  2. Failure and/or intolerance to standard chemotherapy
  3. Life expectancy of at least 3 months
  4. ECOG performance status ≤2

Exclusion Criteria:

  1. Patients with clinically symptomatic brain metastases.
  2. Received the following treatments prior to Visit 2:

    • Cytotoxic or cytostatic anti-cancer chemotherapy within 4 weeks
    • Total resection or irradiation of the target lesion
    • Antibody therapy within 4 weeks and vaccines within 12 weeks
    • Tyrosin kinase inhibitors within 4 weeks
    • Any investigational agent within 4 weeks
  3. Diarrhea CTCAE >1
  4. Skin rash CTCAE >1
  5. Abnormal organ or bone marrow function.
  6. Use of immunosuppressive agents for the past 4 weeks prior to trial start, including systemic corticosteroids used at doses above 20mg/day of prednisolone or equivalent.
  7. History of other malignancy within 5 years prior to trial start, with the exception of basal cell carcinoma of the skin and carcinoma in situ of the cervix (not in Part A).
  8. Active severe infection, any other concurrent disease or medical conditions that are deemed to interfere with the conduct of the trial as judged by the investigator.
  9. Known HIV positive
  10. Known active hepatitis B or C
  11. Patients with known uncontrolled allergic conditions or allergy to the study drug and/or their components.
  12. Clinically significant cardiac disease including unstable angina, acute myocardial infarction within six months from Visit 1, congestive heart failure, and arrhythmia requiring therapy, with the exception of extra systoles or minor conduction abnormalities and controlled and well treated chronic atrial fibrillation.
  13. Significant concurrent, uncontrolled medical condition evaluated by the investigator to interfere with effect of the trial drug.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01117428

United States, Texas
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas, United States, 78229
UZ Brussel, Medische Oncologie
Brussel, Belgium, 1090
UZ Gasthuisberg, Digestive Oncology Unit
Brussel, Belgium, 3000
UZ Antwerp, Oncologie
Edegem, Belgium, 2650
Medical Oncology Department, Vall d´Hebron University Hospital
Barcelona, Spain, 08035
Servicio de Oncología Médica, Hospital Universitario Virgen del Rocío
Sevilla, Spain, 41013
Hospital Clínico Universitario de Valencia
Valencia, Spain, 46010
Sponsors and Collaborators
Symphogen A/S
Principal Investigator: Josep Tabernero, Dr. Hospital Vall d'Hebron BCN ES
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Symphogen A/S Identifier: NCT01117428     History of Changes
Other Study ID Numbers: Sym004-01
2009-017119-13 ( EudraCT Number )
Study First Received: April 23, 2010
Last Updated: December 23, 2015

Keywords provided by Symphogen A/S:
Advanced solid tumors
Metastatic colorectal Cancer

Additional relevant MeSH terms:
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases processed this record on June 23, 2017